Dr. Bogdana Schmidt

So anything else that you wanted to highlight on this? Because I think there's still quite a bit to talk about with Niagara.

So anything else that you wanted to highlight on this? Because I think there's still quite a bit to talk about with Niagara.

So anything else that you wanted to highlight on this? Because I think there's still quite a bit to talk about with Niagara.

Now, I agree with you. I think it's hard to ignore the data, and truly an overall survival benefit is incredibly meaningful, and it's what we've been wanting for these patients for a long time. A couple of practical questions I have in this space for you. So, obviously, there's still some nuance, but as this gets more broadly adapted,

Now, I agree with you. I think it's hard to ignore the data, and truly an overall survival benefit is incredibly meaningful, and it's what we've been wanting for these patients for a long time. A couple of practical questions I have in this space for you. So, obviously, there's still some nuance, but as this gets more broadly adapted,

Now, I agree with you. I think it's hard to ignore the data, and truly an overall survival benefit is incredibly meaningful, and it's what we've been wanting for these patients for a long time. A couple of practical questions I have in this space for you. So, obviously, there's still some nuance, but as this gets more broadly adapted,

adopted, what do you think we as surgeons need to be looking out for taking care of these patients perioperatively? I say this because that duralumab they're getting before, right, oftentimes managed by the medical oncology team. But in the acute post-op setting, we Generally, hopefully, you know, our patients do great, go home on day four and everything's smooth as butter.

adopted, what do you think we as surgeons need to be looking out for taking care of these patients perioperatively? I say this because that duralumab they're getting before, right, oftentimes managed by the medical oncology team. But in the acute post-op setting, we Generally, hopefully, you know, our patients do great, go home on day four and everything's smooth as butter.

adopted, what do you think we as surgeons need to be looking out for taking care of these patients perioperatively? I say this because that duralumab they're getting before, right, oftentimes managed by the medical oncology team. But in the acute post-op setting, we Generally, hopefully, you know, our patients do great, go home on day four and everything's smooth as butter.

But knowing that they have gotten a perioperative checkpoint, do we need to be looking for other things post-op or in the acute periop period and not ignoring it, not thinking, oh, this is just nothing?

But knowing that they have gotten a perioperative checkpoint, do we need to be looking for other things post-op or in the acute periop period and not ignoring it, not thinking, oh, this is just nothing?

But knowing that they have gotten a perioperative checkpoint, do we need to be looking for other things post-op or in the acute periop period and not ignoring it, not thinking, oh, this is just nothing?

There were a couple patients who were pushed out for surgery, though. So they delayed time cystectomy. I don't know how that'll happen in the real world.

There were a couple patients who were pushed out for surgery, though. So they delayed time cystectomy. I don't know how that'll happen in the real world.

There were a couple patients who were pushed out for surgery, though. So they delayed time cystectomy. I don't know how that'll happen in the real world.

Yeah, I absolutely agree. I think to me, that's my main takeaway is if something doesn't look absolutely routine, my first phone calls to my medical oncologist and say, could this be immune related? What do I need to send? What other studies do you want me to get? And be thoughtful about that. With the amount of patients with variant histologies on this trial, it was up to 20%.

Yeah, I absolutely agree. I think to me, that's my main takeaway is if something doesn't look absolutely routine, my first phone calls to my medical oncologist and say, could this be immune related? What do I need to send? What other studies do you want me to get? And be thoughtful about that. With the amount of patients with variant histologies on this trial, it was up to 20%.

Yeah, I absolutely agree. I think to me, that's my main takeaway is if something doesn't look absolutely routine, my first phone calls to my medical oncologist and say, could this be immune related? What do I need to send? What other studies do you want me to get? And be thoughtful about that. With the amount of patients with variant histologies on this trial, it was up to 20%.

Are you seeing this as a positive, meaning you would extend this, basically this treatment paradigm to those patients up front, or do you want more data for that specific patient population?

Are you seeing this as a positive, meaning you would extend this, basically this treatment paradigm to those patients up front, or do you want more data for that specific patient population?